Lupin moves up on launching Penicillamine Tablets USP
Lupin is currently trading at Rs. 1053.30, up by 30.75 points or 3.01% from its previous closing of Rs. 1022.55 on the BSE.
The scrip opened at Rs. 1024.00 and has touched a high and low of Rs. 1057.40 and Rs. 1024.00 respectively. So far 74914 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1121.85 on 18-Sep-2020 and a 52 week low of Rs. 505.00 on 13-Mar-2020.
Last one week high and low of the scrip stood at Rs. 1060.00 and Rs. 909.55 respectively. The current market cap of the company is Rs. 47714.00 crore.
The promoters holding in the company stood at 46.88%, while Institutions and Non-Institutions held 40.05% and 12.79% respectively.
Lupin has launched Penicillamine Tablets USP, 250 mg, having received an approval from the United States Food and Drug Administration (U.S. FDA) earlier.
Penicillamine Tablets USP, 250 mg, are the generic equivalent of Depen Tablets, 250 mg, of Mylan Specialty, L.P., and indicated in the treatment of Wilson’s disease, Cystinuria, and in patients with severe, active rheumatoid arthritis who have failed to respond to an adequate trial of conventional therapy.
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.
